secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOXYTRAN, INC (BIXT)
CIK:        0001445815
Form:       8-K
Filed at:   2026-08-11T11:00:24+00:00
Accession:  0001493152-26-036977
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bioxytran reports first CIDP patient on PLICID shows functional gains; no adverse events
--------------------------------------------------------------------------------

- First CIDP patient treated with once-weekly IV PLICID regained finger use and ability to walk miles.
- No adverse events reported during treatment; company cites case as supporting further evaluation.
- PLICID is an ASI-designed galectin antagonist; Bioxytran plans a larger clinical study.
- Company acknowledges single-patient observations are not sufficient to establish safety or efficacy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1445815/000149315226036977/0001493152-26-036977-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1445815/000149315226036977/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-036977

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer